ERBB2 and non-small cell lung carcinoma: Moreover, EGFR-TKI resistance can be mediated by HER2 gene amplification or protein overexpression [33], providing a rationale for the use of HER2-targeted agents such as lapatinib, trastuzumab or dacomitinib in combination with EGFR-TKIs to treat NSCLC patients who develop HER2 alterations [34].